ERA-EDTA Congress 2011: Late Breaking Clinical Trials II - PR Newswire (press release) PDF Print
PR Newswire (press release)
Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached the end point "end stage renal disease",

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.